Cornèr Bank Group Completes Migration of 2.1m Cards to Vestigo’s Card Management Solution
Cornèr Bank Group, issuer of credit and prepaid cards to private individuals and businesses in Europe, has reached a major milestone in its digital transformation journey by completing migration of its card portfolios across all products and markets to a modern, consolidated solution. Vestigo is a European software provider in cards and account-to-account payments space, and its card management system (CMS) is the key component of the overall solution at Cornèr.
Cornèr Bank Group issues more than /2.1/ million credit and prepaid, Visa, Mastercard and Diners cards directly and through partnerships with hundreds of organizations of various sizes in a B2B2C / co-brand business model. The new solution, managed in-house on a single instance, will further improve innovation and quality of service to Cornèr Bank Group’s partners and ultimate cardholders, as well as enhance internal efficiency. Vestigo’s integrated, modular, “multi-everything” solution is fully customer centric, can manage all types of cards, as well as account-to-account payments, and allows for easy integration leveraging 200+ APIs.
This large-scale implementation and migration project was designed to minimize risk and consisted of multiple phases taking into account requirements regarding different markets, products and legacy systems.
Ing. Vittorio Cornaro, Chief Executive Officer of Cornèr Bank Group, said: “Partnering with a trusted partner like Vestigo helps us modernize and consolidate our pan-European card business, which is the key step of our strategy to transform Cornèr into an agile bank delighting our clients and partners every day with best-in-class products and services”
Simone Tettamanti, CIO at Cornèr Banca, added: This complex, large-scale project was an excellent example of two organizations working together successfully as trusted partners towards a common goal, using agile approach. This modern platform will facilitate Cornèr’s business growth and provide us with flexibility to adjust to evolving customer requirements in the future.”
Kata Kamenski, Chief Executive Officer and Co-founder of Vestigo said: “We’re incredibly proud to work with Cornèr, as this further validates Vestigo’s functionality fit, as well as delivery ability fit with sophisticated, innovative financial institutions. Vestigo continues growing strongly, driven by its differentiating capability to drive convergence across cards and account-to-account payments. Our solution is scalable and can be deployed as on-prem, cloud installation or SaaS.”
About Cornèr Bank Group
Founded in Lugano in 1952, the Cornèr Bank Group is an independent Swiss private bank group operating as a full-service bank. Lugano is Switzerland’s third-largest banking centre, after Zurich and Geneva. Active across the whole range of traditional banking services, the Cornèr Bank Group specializes in the private banking sector, as well as in the areas of lending, Visa, Mastercard and Diners Club payment cards (Cornèrcard) and online trading (Cornèrtrader) – the core businesses on which the growth of the Cornèr Bank Group is based. The Cornèr Bank Group comprises the Lugano-based parent bank Cornèr Bank Ltd., the four branches in Chiasso, Geneva, Locarno and Zurich, the branch BonusCard and the affiliates Cornèr Bank (Overseas) Limited, Cornèrcard UK Ltd., Cornèr Europe AG, Diners Club Italia S.r.l. and Dinit d.o.o.
For more information on Cornèr please visit: www.cornergroup.ch
About Vestigo
Vestigo is a founder-owned paytech, fully focused on cards (CMS) and account-to-account payments (PaymentsHub) space. Vestigo’s newest module HolisticPay is a rich payments modernization & convergence layer designed to facilitate managed cards & payments modernization. Our continuously increasing team has more than 130 employees. Vestigo’s modern, modular, customer-centric solution creates value for financial institution clients in payments, issuing and acquiring businesses. We differentiate by bringing the cards and account payments together in a fully customer centric way using modern technology. Vestigo currently supports clients in 7 European countries, with a strong growth strategy into further markets.
For more information on Vestigo please visit: www.vestigo.hr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005043/en/
Contact information
Cornèr Media Contact
Anna Russo, Head of PR
T +41 91 800 53 54
E anna.russo@corner.ch
Vestigo Media Contact:
Valbona Guscic
T +385 91 6392902
E valbona.guscic@vestigo.hr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom